UY28650A1 - Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta - Google Patents

Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta

Info

Publication number
UY28650A1
UY28650A1 UY28650A UY28650A UY28650A1 UY 28650 A1 UY28650 A1 UY 28650A1 UY 28650 A UY28650 A UY 28650A UY 28650 A UY28650 A UY 28650A UY 28650 A1 UY28650 A1 UY 28650A1
Authority
UY
Uruguay
Prior art keywords
conduct
memantine
prevention
treatment
suicide
Prior art date
Application number
UY28650A
Other languages
English (en)
Inventor
Charles Flicker
Heikki Hakkarainen
Scott Mcdonald
Original Assignee
Forest Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forest Laboratories filed Critical Forest Laboratories
Publication of UY28650A1 publication Critical patent/UY28650A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Abstract

La presente invención se relaciona con el tratamiento del trastorno depresivo mayor (TDM), así como con la prevención de la conducta suicida asociada con el mismo, mediante la utilización de memantina, un antagonista no competitivo del receptor de NMDA.
UY28650A 2003-12-05 2004-12-02 Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta UY28650A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52726803P 2003-12-05 2003-12-05

Publications (1)

Publication Number Publication Date
UY28650A1 true UY28650A1 (es) 2005-02-28

Family

ID=34676726

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28650A UY28650A1 (es) 2003-12-05 2004-12-02 Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta

Country Status (13)

Country Link
US (1) US20050282911A1 (es)
EP (1) EP1694316A1 (es)
JP (1) JP2007513169A (es)
KR (1) KR20070051770A (es)
CN (1) CN1889938A (es)
AR (1) AR046868A1 (es)
AU (1) AU2004296790A1 (es)
CA (1) CA2546496A1 (es)
EA (1) EA200601103A1 (es)
MX (1) MXPA06006397A (es)
TW (1) TW200519067A (es)
UY (1) UY28650A1 (es)
WO (1) WO2005055996A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
DK1793671T3 (da) * 2004-09-20 2011-08-22 Sinai School Medicine Anvendelse af memantin (namenda) til behandling af autisme, tvangstilstand og impulsivitet
TWI319708B (en) * 2005-10-14 2010-01-21 Methods and compositions for altering cell fuction
US8865763B2 (en) 2005-10-14 2014-10-21 Alltech, Inc. Methods and compositions for altering cell function
US8871715B2 (en) 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
US7621871B2 (en) * 2006-06-16 2009-11-24 Archinoetics, Llc Systems and methods for monitoring and evaluating individual performance
US8682445B2 (en) * 2006-07-28 2014-03-25 Cyberonics, Inc. Patient management system for treating depression using an implantable medical device
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
CA2772488C (en) 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
EP2758134B1 (en) * 2011-09-19 2019-05-29 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
US20140243211A1 (en) 2013-02-28 2014-08-28 Indiana University Research & Technology Corporation Blood biomarkers for suicidality
EP3307910A4 (en) 2015-06-12 2019-05-22 Indiana University Research & Technology Corporation PREDICTION OF SELF-SUDDENCE BY USING A COMBINED GENOMIC AND CLINICAL RISK ASSESSMENT
CA3105451A1 (en) * 2017-05-12 2018-11-15 Indiana University Research And Technology Corporation Precision medicine for treating and preventing suicidality
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
US20220008398A1 (en) * 2018-11-21 2022-01-13 Certego Therapeutics Gaboxadol for reducing risk of suicide and rapid relief of depression
CA3130180A1 (en) * 2019-02-22 2020-08-27 Theis Terwey Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders
WO2021236876A2 (en) 2020-05-20 2021-11-25 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
EP0392059B1 (de) * 1989-04-14 1993-09-15 Merz & Co. GmbH & Co. Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
DE19644998C1 (de) * 1996-10-30 1998-06-10 Hanns Prof Dr Ludwig Verwendung von Adamantanaminen oder strukturanaloger Verbindungen zur Bekämpfung von Borna Disease Virus und zur Prophylaxe und Behandlung von Affekterkrankungen und anderen mit BDV-Infektionen verbundenen Störungen bei Mensch und Tier
US6071966A (en) * 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
UA61962C2 (uk) * 1997-06-30 2003-12-15 Мерц Фарма Гмбх Унд Ко. Кгаа Сполука 1-аміноалкілциклогексану, фармацевтична композиція на її основі та спосіб лікування
WO2002045710A1 (en) * 2000-12-07 2002-06-13 Neuromolecular Inc. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
CA2529857A1 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US20050065219A1 (en) * 2003-03-27 2005-03-24 Lipton Stuart A. Treatment of demyelinating conditions

Also Published As

Publication number Publication date
CA2546496A1 (en) 2005-06-23
CN1889938A (zh) 2007-01-03
AU2004296790A1 (en) 2005-06-23
TW200519067A (en) 2005-06-16
AR046868A1 (es) 2005-12-28
WO2005055996A1 (en) 2005-06-23
MXPA06006397A (es) 2006-08-23
EP1694316A1 (en) 2006-08-30
EA200601103A1 (ru) 2006-10-27
KR20070051770A (ko) 2007-05-18
US20050282911A1 (en) 2005-12-22
JP2007513169A (ja) 2007-05-24

Similar Documents

Publication Publication Date Title
UY28650A1 (es) Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
CY1120297T1 (el) Ρυθμιστες υποδοχεα ανδρογονου και χρησεις αυτων
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
PA8576901A1 (es) Moduladores del receptor de glucocorticoides
ECSP17077930A (es) Métodos y kits para tratar la depresión
ECSP11011127A (es) ANTICUERPO ANTI-cMET NOVEDOSO
ECSP10010409A (es) INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
MY191407A (en) Certain chemical entities, compositions and methods
ECSP088817A (es) Métodos para usar el receptor gpr119 en la identificación de compuestos útiles para aumentar la masa ósea en un individuo
BR122019021238B8 (pt) uso de um inibidor do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd)
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
NO20073293L (no) Toll-liknende reseptor-3-antagonister, fremgangsmater og anvendelser
DE602007006961D1 (de) Cgrp-rezeptorantagonisten
ECSP10010042A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
BRPI0612674B8 (pt) preparação farmacêutica, uso de um antagonista do receptor de angiotensina ii e um bloqueador do canal de cálcio
MX2022002633A (es) Mimeticos de hepcidina conjugada.
EP1906968A4 (en) NEW SCHEMES FOR ORAL MONOPHASIC CONTRAZEPTIVA
BRPI0519031A2 (pt) compostos e composiÇÕes como moduladores de atividades de receptores esteroidais e de canal de cÁlcio
AR058173A1 (es) Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas
TW200744567A (en) Phenylethylamine analogs and their use for treating glaucoma
CY1113154T1 (el) Συνδυασμος του αναληπτικου modafinil και ενος αντικαταθλιπτικου για τη θεραπεια της καταθλιψης
CR11562A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina
CL2009000660A1 (es) Uso de un antagonista del receptor 2 activado con proteasa (par2) para tratar, inhibir o aliviar el dolor.
BR112021025537A2 (pt) Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásica
BRPI0608287A2 (pt) agente endoparasiticida

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150609